Abstract
Aim To investigate the utility of serum proteins to predict new-onset heart failure (HF), including those with reduced or preserved ejection fraction (HFrEF or HFpEF), with or without the consideration of known HF-associated clinical variables.
Methods and results The study included 612 participants with HF events from the prospective population-based AGES-Reykjavik cohort of the elderly (N = 5457), 440 of whom were incident cases, with a median follow-up time of 5.45 years. The incident HF population with echocardiographic data included patients with HFrEF (n = 167) and HFpEF (n = 188). The least absolute shrinkage and selection operator (LASSO) model in conjunction with bootstrap resampling validation (500 replications) were used to select predictor variables based on the analysis of 4782 serum proteins and numerous clinical variables related to HF. In at least 80% of bootstrap replications, a subset of 8 to 13 serum proteins had non-zero coefficients for predicting all incident HF, HFpEF, or HFrEF separately. We used C-statistics to assess the goodness of fit when modeling a prognostic risk score for incident HF. In the null model, which did not take age, sex or clinical variables into account, 13 proteins combined had a C-index of 0.80 for all incident HF, whereas for incident HFpEF and HFrEF, the C-index for a subset of 8 or 10 protein predictors combined was 0.78 and 0.80, respectively. The concordance gain for each set of protein predictors was also investigated in the context of the approved biomarker NPPB as well as a number of clinical variables such as Framingham risk score components and calcium in the coronary artery and thoracic aorta. We show that these proteins improve prediction of future HF events even when a large number of HF-associated clinical variables are not included in the model.
Conclusion A small number of circulating proteins were found to accurately predict new-onset HF when no demographic or other information was included, and they also improved the prediction when the main known biomarker NPPB and many HF-associated clinical risk factors of the condition were taken into account.
Competing Interest Statement
Lori L. Jennings is an employee and stockholder of Novartis. All other authors have no conflict of interests to declare.
Funding Statement
National Institute on Aging (NIA) contracts N01-AG-12100 and HHSN271201200022C for V.G. financed the study. V. Gudnason received a funding from the NIA (1R01AG065596-01A1), and IHA received a grant from Althingi (the Icelandic Parliament). The Icelandic Research Fund (IRF) funded V. Emilsson and V. Gudmundsdottir with grants 195761-051, 184845-053, and 206692-051, while V. Gudmundsdottir received a postdoctoral research grant from the University of Iceland Research Fund
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All AGES-RS participants are of European ancestry. AGES-RS was approved by the National Bioethics Committee in Iceland that acts as the institutional review board for the Icelandic Heart Association (approval number VSN-00-063, in accordance with the Helsinki Declaration) and by the US National Institutes of Health, National Institute on Aging Intramural Institutional Review Board. All participants gave informed, multistage consent prior to enrollment.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared first authors
Data Availability
The custom-design Novartis SOMAscan data are available through a collaboration agreement with the Novartis Institutes for BioMedical Research (lori.jennings{at}novartis.com). Data from the AGES Reykjavik study are available through collaboration (AGES_data_request{at}hjarta.is) under a data usage agreement with the IHA. All access to data is controlled via the use of a subject-signed informed consent authorization. The time it takes to respond to requests varies depending on their nature and circumstances of the request, but it will not exceed 14 working days. All data supporting the conclusions of the paper are presented in the main text and freely available as a supplement to this manuscript
